Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Acquired by Barclays PLC

Barclays PLC increased its position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 367.1% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 124,141 shares of the company’s stock after purchasing an additional 97,565 shares during the period. Barclays PLC’s holdings in Fulcrum Therapeutics were worth $443,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. National Bank of Canada FI boosted its holdings in shares of Fulcrum Therapeutics by 869.6% in the second quarter. National Bank of Canada FI now owns 4,460 shares of the company’s stock valued at $28,000 after acquiring an additional 4,000 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in Fulcrum Therapeutics by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company’s stock worth $43,000 after purchasing an additional 4,701 shares during the period. SG Americas Securities LLC grew its position in Fulcrum Therapeutics by 26.5% during the 3rd quarter. SG Americas Securities LLC now owns 33,019 shares of the company’s stock worth $118,000 after purchasing an additional 6,926 shares during the last quarter. Profund Advisors LLC acquired a new position in Fulcrum Therapeutics in the second quarter valued at $68,000. Finally, American Century Companies Inc. raised its holdings in shares of Fulcrum Therapeutics by 13.2% in the second quarter. American Century Companies Inc. now owns 104,371 shares of the company’s stock valued at $647,000 after buying an additional 12,167 shares during the last quarter. 89.83% of the stock is owned by institutional investors and hedge funds.

Fulcrum Therapeutics Stock Performance

NASDAQ:FULC opened at $5.08 on Friday. Fulcrum Therapeutics, Inc. has a 1 year low of $2.86 and a 1 year high of $13.70. The stock has a fifty day moving average price of $3.81 and a two-hundred day moving average price of $5.61. The stock has a market capitalization of $274.01 million, a price-to-earnings ratio of -16.39 and a beta of 2.14.

Analysts Set New Price Targets

A number of research firms recently issued reports on FULC. Leerink Partners reissued a “market perform” rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a report on Thursday, September 12th. Cantor Fitzgerald downgraded Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Thursday, September 12th. Royal Bank of Canada restated a “sector perform” rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a research note on Thursday, November 14th. Bank of America lowered shares of Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating and lowered their price objective for the company from $10.00 to $2.00 in a research report on Thursday, September 12th. Finally, Leerink Partnrs downgraded shares of Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 12th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $9.33.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.